Clinical Trial Update: Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated upfront and maintenance obinutuzumab in mantle cell lymphoma treated with the DHAP regimen and MRD-driven maintenance. The study ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED